{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:12:15Z","timestamp":1791684735805,"version":"4.3.4"},"reference-count":42,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,2,27]]},"DOI":"10.18632\/oncotarget.24310","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T17:52:05Z","timestamp":1516816325000},"page":"13023-13035","source":"Crossref","is-referenced-by-count":77,"title":["First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL"],"prefix":"10.18632","volume":"9","author":[{"given":"John C.","family":"Byrd","sequence":"first","affiliation":[{"name":"Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"Division of Oncology, Washington University, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Sharman","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute and Research Center, US Oncology, Eugene, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy I.","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute, Stanford School of Medicine, Stanford, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Augustson","sequence":"additional","affiliation":[{"name":"Sir Charles Gairdner Hospital, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Marlton","sequence":"additional","affiliation":[{"name":"Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Renee Commerford","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Okrah","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Murray","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elicia","family":"Penuel","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley F.","family":"Ward","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"Blood Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,1,22]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Hamdy","year":"2013","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1084\/jem.191.10.1735","article-title":"Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation","volume":"191","author":"Wortis","year":"2000","journal-title":"J Exp Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Fraser","year":"2016","journal-title":"Nat Commun"},{"key":"5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Heerema","year":"2013","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Ghia","year":"2016","journal-title":"N Engl J Med"},{"key":"8","first-page":"1278","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"James","year":"2013","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia","volume":"30","author":"Kipps","year":"2012","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Lister","year":"2007","journal-title":"J Clin Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chen-Kiang","year":"2014","journal-title":"Cancer Discov"},{"key":"12","doi-asserted-by":"crossref","first-page":"36953","DOI":"10.1074\/jbc.M707682200","article-title":"Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase","volume":"282","author":"O'Neill","year":"2007","journal-title":"J Biol Chem"},{"key":"13","first-page":"226","article-title":"BTK small molecule inhibitors induce a distinct pancreatic toxicity in rats","volume":"360","author":"Crawford","year":"2016","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1208\/s12248-014-9682-8","article-title":"Emerging technologies to increase ligand binding assay sensitivity","volume":"17","author":"Mikulskis","year":"2015","journal-title":"AAPS J"},{"key":"15","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Johnson","year":"2014","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Davies","year":"2014","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Kipps","year":"2008","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2567.2007.02693.x","article-title":"Defective Toll-like receptor 9-mediated cytokine production in B cells from Bruton's tyrosine kinase-deficient mice","volume":"123","author":"Vargas","year":"2008","journal-title":"Immunology"},{"key":"19","first-page":"156","article-title":"Rituximab in chronic lymphocytic leukemia","volume":"47","author":"Byrd","journal-title":"Semin Hematol"},{"key":"20","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"O'Brien","year":"2015","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1084\/jem.188.7.1297","article-title":"Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase","volume":"188","author":"Clark","year":"1998","journal-title":"J Exp Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations","volume":"11","author":"Franke","year":"2016","journal-title":"ACS chemical biology"},{"key":"23","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Wagner-Johnston","year":"2014","journal-title":"Blood"},{"key":"24","first-page":"71","article-title":"Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia","volume":"3","author":"Hendriks","year":"2013","journal-title":"American journal of blood research"},{"key":"25","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","article-title":"Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice","volume":"119","author":"Hendriks","year":"2012","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia","volume":"1","author":"Flynn","year":"2015","journal-title":"JAMA Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Davis","year":"1997","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Noto","year":"2016","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"Heerema","year":"2014","journal-title":"The Lancet Oncology"},{"key":"30","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1074\/jbc.M009137200","article-title":"Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes","volume":"276","author":"Khan","year":"2001","journal-title":"J Biol Chem"},{"key":"31","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Burger","year":"2012","journal-title":"Blood"},{"key":"32","article-title":"Evaluation of the novel Bruton\u2032s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK","volume":"34","author":"Franke","year":"2016","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2","volume":"198","author":"Pals","year":"2003","journal-title":"J Exp Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens","volume":"121","author":"Keating","year":"2015","journal-title":"Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1373\/clinchem.2007.091181","article-title":"Ultrasensitive flow-based immunoassays using single-molecule counting","volume":"53","author":"Goix","year":"2007","journal-title":"Clin Chem"},{"key":"36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Zehnder","year":"2015","journal-title":"N Engl J Med"},{"key":"37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Radford","year":"2013","journal-title":"N Engl J Med"},{"key":"38","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Gobessi","year":"2014","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib","volume":"370","author":"Yilmaz","year":"2014","journal-title":"N Engl J Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK C481S Mediated Resistance to Ibrutinib in CLL","volume":"35","author":"Mantel","year":"2017","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Staudt","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"42","unstructured":"Young, Crawford. Discovery of GDC-0853: A highly potent, selective, and non-covalent BTK inhibitor. In Annual meeting of the American Chemical Society. San Diego, CA. 2016."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T18:35:05Z","timestamp":1719772505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,22]]},"references-count":42,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2018,2,27]]}},"alternative-id":["24310","29560128"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24310","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,22]]}}}